These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28325153)

  • 1. Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease.
    Brotini S; Schievano C; Guidi L
    CNS Neurol Disord Drug Targets; 2017; 16(6):705-713. PubMed ID: 28325153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
    Orefice NS; Alhouayek M; Carotenuto A; Montella S; Barbato F; Comelli A; Calignano A; Muccioli GG; Orefice G
    Neurotherapeutics; 2016 Apr; 13(2):428-38. PubMed ID: 26857391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
    Impellizzeri D; Bruschetta G; Cordaro M; Crupi R; Siracusa R; Esposito E; Cuzzocrea S
    J Neuroinflammation; 2014 Aug; 11():136. PubMed ID: 25164769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.
    Marcucci M; Germini F; Coerezza A; Andreinetti L; Bellintani L; Nobili A; Rossi PD; Mari D
    Trials; 2016 Jul; 17():369. PubMed ID: 27473188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Effects of Ultramicronized Palmitoylethanolamide (PEA-um) in Myocardial Ischaemia and Reperfusion Injury in VIVO.
    Di Paola R; Cordaro M; Crupi R; Siracusa R; Campolo M; Bruschetta G; Fusco R; Pugliatti P; Esposito E; Cuzzocrea S
    Shock; 2016 Aug; 46(2):202-13. PubMed ID: 26844976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
    Ardizzone A; Fusco R; Casili G; Lanza M; Impellizzeri D; Esposito E; Cuzzocrea S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
    Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
    J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palmitoylethanolamide/Luteolin as Adjuvant Therapy to Improve an Unusual Case of Camptocormia in a Patient with Parkinson's Disease: A Case Report.
    Brotini S
    Innov Clin Neurosci; 2021; 18(10-12):12-14. PubMed ID: 35096476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial.
    Andresen SR; Bing J; Hansen RM; Biering-Sørensen F; Johannesen IL; Hagen EM; Rice ASC; Nielsen JF; Bach FW; Finnerup NB
    Pain; 2016 Sep; 157(9):2097-2103. PubMed ID: 27227691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms.
    Passavanti MB; Fiore M; Sansone P; Aurilio C; Pota V; Barbarisi M; Fierro D; Pace MC
    BMC Anesthesiol; 2017 Dec; 17(1):171. PubMed ID: 29258432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.